Imatinib Mesylate Tablet, Film Coated
Product Images NDC 42292-044

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 42292-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib Structural Formula (Image 01)

Chemical structure diagram of imatinib mesylate, the active ingredient in Imatinib Mesylate tablets. The structure displays molecular bonds and groups including a mesylate moiety.*

FDA Label Image

Imatinib Mesylate 100 mg Tablets Unit Carton Label (Image 02)

Imatinib Mesylate 100 mg film-coated tablets in a carton label from Mylan Institutional Inc. The label shows the tablet image, dosage strength (100 mg), quantity (30 tablets, 3x10), and includes storage instructions along with manufacturer details from Mylan Pharmaceuticals Inc.*

FDA Label Image

Imatinib Mesylate 400 mg Tablets Unit Carton Label (Image 03)

The image shows the front and back of a blue unit-dose package distributed by Mylan Institutional Inc, Rockford, IL. The package includes warnings that it is not child resistant, intended for institutional use only, and provides light resistance. The back features a small white label with a QR code and placeholders for NDC, expiration date, and lot number. No specific drug strength or name is visible on the package.*

FDA Label Image

Figure 1: Progression Free Survival (itt Principle) (Image 04)

A Kaplan-Meier survival curve chart comparing the percentage of patients without progression over months since randomization between two groups: Imatinib arm (solid line) and IFN+Ara-C arm (dashed line). The chart includes patient counts at progression and follow-up, as well as a hazard ratio with confidence interval and p-value for the comparison.*

FDA Label Image

Figure 2: Time To Progression To Ap Or Bc (itt Principle) (Image 05)

A survival curve chart comparing the percentage of patients without progression to AP/BC over 72 months since randomization between two treatment arms: Imatinib and IFN+Ara-C. The chart includes hazard ratio statistics and patient numbers for each group, illustrating better progression-free survival in the Imatinib arm.*

FDA Label Image

Unit Carton (Image 06)

Imatinib Mesylate 400 mg film-coated tablets packaging label showing oblong, brown tablets imprinted with 'I 400'. The label includes the NDC 42292-044-03, indicates a 30 tablet count (3 x 10), and states that it is Rx only. Storage instructions and manufacturer details for Mylan Pharmaceuticals Inc. are also included.*

FDA Label Image

Unit Carton (Image 07)

A blue unit-dose packaging label for Imatinib Mesylate tablets distributed by Mylan Institutional Inc., Rockford, IL. The front states the package is not child resistant, for institutional use only, with light-resistant properties and a window for lot number and expiration date. The back displays a white label with a QR code, expiration date, and lot number.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.